Latest Healthcare News

AVITA Medical reported a robust 30% increase in Q4 2024 commercial revenue alongside key FDA clearances, setting the stage for ambitious growth in 2025.

Cochlear Limited posted a 6% increase in HY25 sales revenue driven by strong implant sales but anticipates FY25 profits at the lower end of guidance due to declining services revenue and rising cloud investments.

Cochlear Limited posted a 5% increase in sales revenue to $1.17 billion for the half year ended December 2024, driven by strong cochlear and acoustic implant growth despite a decline in Services revenue. The company anticipates FY25 underlying net profit at the lower end of guidance amid increased cloud investments and prepares for new product launches.

HealthCo Healthcare & Wellness REIT reported a solid 5% increase in Funds From Operations (FFO) and Distribution Per Unit (DPU) for the first half of FY25, underpinned by stable asset valuations and a robust healthcare portfolio.

Cochlear Limited has announced a fully franked dividend of AUD 2.15 per share for the six months ending December 2024, payable in multiple currencies on April 14, 2025.

HealthCo Healthcare & Wellness REIT reports solid 5% growth in FFO and DPU for 1H FY25, maintaining strong occupancy and gearing levels despite ongoing Healthscope lease speculation.

Cochlear Limited has reported a robust half-year performance with a 7% increase in underlying net profit and an 8% rise in interim dividends, driven by strong sales in cochlear and acoustic implants despite a decline in services revenue.

HealthCo Healthcare and Wellness REIT reported a sharp increase in half-year losses to $15.4 million, alongside a portfolio reduction and steady funds from operations, highlighting a complex transition phase.

Pro Medicus has delivered a record first half in FY25, driven by strong revenue growth, major contract wins, and successful implementations that position it well for future expansion.

Althea Group Holdings has sharply downgraded its FY25 financial guidance, citing significant challenges in its medicinal cannabis division and the strategic withdrawal from a vape product initiative. Despite the setback, the company highlights ongoing growth in its recreational cannabis operations and a strategic refocus on capital efficiency.

Pro Medicus Limited has announced a fully franked ordinary dividend of AUD 0.25 per share for the six months ending December 2024, signaling continued shareholder returns without the need for external approvals.

Pro Medicus Limited has delivered a record interim profit of $51.7 million, boosted by major North American contract wins and strong margin expansion.